A feature documentary about disgraced Theranos founder Elizabeth Holmes has become one of the most discussed titles of the autumn after critics handed it a perfect aggregate review score, with several reviewers describing the film as a masterpiece. The reaction began circulating widely on entertainment forums and social platforms this week, driving renewed attention to a fraud case that has already produced best-selling books, a podcast, an HBO documentary and an Emmy-winning drama series.
The headline figure — a flawless critics’ score on review aggregators — is the kind of number that travels fast online. It is also the kind of number that deserves context: perfect scores are common for documentaries in the earliest stage of a release, when only a handful of festival or press reviews have been counted, and they frequently slip once wider coverage lands.
What is being claimed
The trending item making the rounds says the documentary has drawn unanimous critical praise, with reviewers singling out its archival research and its refusal to treat Holmes as a novelty villain. Commenters have repeatedly pointed to the film’s use of original footage — internal Theranos material, promotional videos, depositions and television appearances — as the element that distinguishes it from earlier treatments of the story.
Readers should treat the specific numbers with care. Aggregate scores are moving targets, review counts matter as much as percentages, and the distributor, exact title and release window attached to viral posts about the film have not been consistently reported across outlets. Anyone planning to watch should check the aggregator page and the platform listing directly rather than relying on a screenshot.
The case the film is built on
The underlying facts of the Theranos collapse are well established through court records and years of reporting. Holmes dropped out of Stanford University in 2003 and founded the company that became Theranos, promising a device that could run dozens of diagnostic tests from a few drops of blood taken by finger prick. The pitch attracted roughly $945 million from investors and produced a paper valuation of about $9 billion, along with magazine covers that cast Holmes as the first self-made female technology billionaire.
The company’s board at various points included former US secretaries of state Henry Kissinger and George Shultz, former defense secretary James Mattis and former senator Sam Nunn. Theranos also struck a retail partnership with Walgreens, placing blood-draw centres inside pharmacies in Arizona and California.
Reporting by John Carreyrou at The Wall Street Journal, beginning in October 2015, revealed that the company’s proprietary analyser handled only a small fraction of its tests and that most samples were being processed on modified commercial machines made by other manufacturers. Federal regulators subsequently found serious deficiencies at the company’s laboratory, and Theranos voided or corrected tens of thousands of test results. The company dissolved in 2018.
The convictions
- In January 2022, a federal jury in San Jose convicted Holmes on four counts — one count of conspiracy to defraud investors and three counts of wire fraud. She was acquitted on four counts relating to patients, and the jury could not reach a verdict on three further counts.
- In November 2022, US District Judge Edward Davila sentenced Holmes to 11 years and three months in prison. She reported to a federal prison camp in Bryan, Texas, on 30 May 2023.
- Her sentence was later reduced by roughly two years through federal credit calculations, moving her projected release into the early 2030s. Appeals against her conviction have been unsuccessful.
- Ramesh “Sunny” Balwani, the company’s former president and Holmes’s former partner, was convicted on 12 counts in July 2022 and sentenced to nearly 13 years.
Holmes has given a small number of interviews from prison, maintaining that she believed in the technology and intends to return to healthcare work. Prosecutors argued at trial that she knowingly misrepresented the device’s capabilities, including by adding pharmaceutical company logos to validation reports those companies had not endorsed.
Why the story keeps returning to screens
Theranos has become shorthand for a specific kind of failure: a founder narrative that outpaced the engineering, sustained by investors who did not insist on independent verification and by coverage that rewarded charisma over data. That framing is what critics appear to be responding to in the new documentary, which reviewers describe as placing the blame net wider than one founder.
The pattern is not confined to medical devices. Debates over inflated terminology in the current technology cycle — including the fight over whether today’s AI systems should be called superintelligence — turn on the same question the Theranos story raised: who checks the claim before the money and the customers arrive. Similar scrutiny has followed other technology procurement disputes, such as the contract clash that led Elgin Community College to cover its Flock surveillance cameras.
How to read a perfect score
Aggregators convert written reviews into a binary positive-or-negative tally, which means a 100% rating signals consensus rather than intensity. A documentary with 12 positive reviews and a documentary with 120 both display the same figure. Audience scores, which open after release, often diverge sharply from critics’ numbers on true-crime and corporate-fraud titles, where viewers frequently object to perceived sympathy toward the subject.
A unanimous score is a useful signal that no critic has panned a film. It is not a measure of how good those critics thought it was.
For audiences deciding whether to watch, the more durable test will be whether the film adds material that was not already public through Carreyrou’s book Bad Blood, Alex Gibney’s 2019 HBO documentary The Inventor: Out for Blood in Silicon Valley, or the 2022 Hulu series The Dropout, for which Amanda Seyfried won an Emmy. Early reviews suggest the new film’s archival access is its strongest card.
NarwhalTV will update this report as release details, distributor confirmation and a larger review sample become available.
